By Dr. Jun Karibe, MD — BIOTOPE Clinic Shirokanedai, Tokyo · Reviewed August 2026
A woman walks into our BIOTOPE clinic in Shirokanedai and describes the same story we hear several times a week.
She is somewhere between 42 and 54 kg. Her diet has not changed. Her exercise has not changed. And yet over the past 18 months, five, seven, sometimes ten kilograms have appeared, most of it deposited around her waist. The jeans that fitted last year now do not close. A recent kenshin returned everything within normal limits and her Japanese GP suggested she eat less and walk more. She has tried both. Nothing is moving.
Perimenopausal weight gain is one of the most common presentations in our nutritional practice, and it is also one of the most systematically misunderstood. The framing that it is a simple energy-balance problem, correctable by eating less and moving more, is not merely unhelpful — it is inaccurate.
The physiology of midlife weight gain in women involves at least six overlapping mechanisms, each of which needs to be addressed on its own terms. Willpower is not the missing ingredient.
This article walks through what actually drives the weight gain of the perimenopausal years, what the nutritional and training levers are that have real published evidence behind them, where the honest limits of nutritional therapy sit, and when it becomes reasonable to consider GLP-1 medication such as semaglutide or tirzepatide as an adjunct. It is written for women in their forties and early fifties living in Tokyo who have been dismissed with the standard advice and want something more clinically grounded to work with.
What is actually happening to your body between 40 and 55
The perimenopausal transition is a hormonal remodelling, not a single event. Weight change during this window has multiple drivers that begin at different times, unfold at different rates, and reinforce one another. Naming them individually is the first step towards intervening on them.
Declining oestrogen sensitivity and insulin resistance
Oestrogen — and specifically oestradiol — is an insulin-sensitising hormone.
Oestrogen receptors are present in liver, skeletal muscle, adipose tissue and the pancreatic beta cell, and oestradiol signalling supports insulin action at each of these sites. As ovarian oestradiol production becomes erratic through perimenopause and then declines through the menopausal transition, tissue insulin sensitivity falls. The pancreas compensates by producing more insulin, and chronically elevated insulin drives fat storage — preferentially into visceral adipose tissue around the abdomen rather than the subcutaneous, gluteofemoral distribution that oestrogen normally favours.[1]
This is the mechanism behind the shift from “pear” to “apple” body composition that many women describe. It is not a change in eating; it is a change in where the same energy is deposited. A 2024 review in Nature Reviews Endocrinology summarised the evidence that the loss of oestrogen action is directly responsible for approximately 5 to 8 percent increases in visceral fat mass over the menopausal transition independent of changes in total body weight.[2]
Sleep debt and cortisol dysregulation
Perimenopausal sleep disruption is not incidental to the weight gain. It is causal. Vasomotor symptoms — night sweats, hot flushes at 3 a.m. — fragment sleep architecture and reduce time in slow-wave sleep, which is the sleep stage most important for growth hormone release and glucose regulation. Even in women who do not consciously experience night waking, actigraphy studies show measurable increases in sleep fragmentation across the transition.
Sleep restriction of even one to two hours per night for a week is enough to reduce insulin sensitivity by 20 to 30 percent in controlled laboratory settings.[3] Chronically fragmented sleep raises evening cortisol, blunts morning cortisol, increases appetite through elevated ghrelin and reduced leptin, and specifically drives cravings for high-carbohydrate, high-fat food the following day.
The cortisol axis then compounds the insulin problem: cortisol itself promotes visceral fat deposition through a specific enzyme pathway (11-beta-HSD1) that is highly expressed in abdominal adipose tissue.
In practical terms this means a perimenopausal woman with fragmented sleep is fighting two-front insulin resistance — one front driven by falling oestrogen, the other by elevated cortisol — while also carrying a stronger appetite signal. Correcting sleep is not adjacent to weight loss in this population; it is often the rate-limiting step.
Sarcopenia and the metabolic rate
Skeletal muscle is the largest reservoir of insulin-mediated glucose disposal in the body and a major determinant of resting metabolic rate. Muscle mass declines from the fourth decade onwards, and the rate of decline accelerates through the menopausal transition, driven partly by the loss of oestrogen (which supports muscle protein synthesis and satellite cell activity) and partly by declining physical activity.
The loss of muscle has a direct effect on daily energy expenditure — each kilogram of muscle lost reduces resting metabolic rate by roughly 10 to 15 kcal per day, which sounds trivial until you consider that a five-kilogram loss of muscle across the transition translates into an unrecovered 50 to 75 kcal per day, or approximately 20 to 27 thousand kcal per year. More importantly, less muscle means less insulin-sensitive tissue, worsening the underlying insulin resistance and creating a feed-forward loop.
Subtle thyroid shifts
Frank thyroid disease presents clearly on standard testing. What is easier to miss are the sub-clinical patterns common in midlife women: a TSH creeping into the upper end of the reference range, a free T3 sitting at the lower end, or a mildly elevated reverse T3 in the context of chronic stress. Anti-thyroid antibodies also rise in prevalence through midlife, and a fraction of women transition into overt autoimmune hypothyroidism during the perimenopausal years.
The Japanese kenshin panel typically measures only TSH, so a woman with normal TSH but low-normal free T3 and elevated antibodies — a picture consistent with early autoimmune hypothyroidism or peripheral T4-to-T3 conversion dysfunction — will be told she is thyroid-normal when in fact her thyroid function is contributing to fatigue, cold sensitivity and weight gain. An extended thyroid panel is standard in our practice for any perimenopausal woman presenting with weight change.
Oestrogen dominance patterns
The term “oestrogen dominance” is used loosely in popular writing, but the underlying pattern is clinically meaningful. Early in perimenopause, oestradiol can still surge in individual cycles while progesterone drops more consistently — because ovulation becomes less regular and the corpus luteum, which produces progesterone, is present less often. The result is an oestrogen-to-progesterone ratio that is skewed high, even though absolute oestradiol may be within a normal range.
This pattern contributes to fluid retention (progesterone is mildly diuretic), breast tenderness, heavier or more erratic bleeding, mood volatility, and a subjective sense of bloating and weight gain that is partly water and partly true adipose expansion driven by unopposed oestrogen stimulation of adipocyte proliferation.
Changes in gut microbiome and bile acid handling
An emerging area of evidence relates to the gut microbiome and specifically the oestrobolome — the collection of gut bacteria that metabolise oestrogens. Perimenopausal shifts in the microbiome alter enterohepatic recycling of oestrogens and short-chain fatty acid production, both of which have downstream effects on insulin sensitivity and inflammation. This is not yet a target for specific therapy in most patients, but it is one of the reasons why the same intervention may produce different results in two women with apparently similar hormonal profiles.
Why the standard advice fails
“Eat less and move more” is not wrong so much as insufficient. In a young adult with a healthy insulin response, energy restriction produces predictable weight loss because insulin drops, lipolysis proceeds, and adipose tissue releases stored energy for use. In a perimenopausal woman with insulin resistance, fragmented sleep and declining muscle mass, energy restriction produces a different sequence of events.
Chronic caloric restriction in this population tends to preferentially reduce lean mass rather than fat mass, because the metabolic environment is already suppressed and the body defends its adipose stores through further reductions in resting metabolic rate.
Cortisol rises further under sustained restriction, worsening abdominal fat deposition. Hunger and cravings intensify. The typical result is a small initial weight loss, a plateau after four to six weeks, and rebound weight gain within six to twelve months — often to a higher body weight than before the restriction started.
The clinical picture we see in Shirokanedai is women who have been through this cycle three or four times over the past decade, each time returning to a higher baseline with less muscle and more visceral fat than before. The next diet is not the answer. A different framework is.
The nutritional levers that actually work
What follows is not a diet plan. It is a set of levers, each with published evidence in the perimenopausal or older adult population, arranged in the order in which we typically prioritise them.
Protein at every meal — the highest-yield change
The protein intake that maintains, let alone builds, muscle in a 45-year-old is higher than the intake that suffices at 25. Current evidence supports 1.2 to 1.6 grams of protein per kilogram of body weight per day in the perimenopausal and menopausal population, distributed across three or four meals rather than concentrated at dinner.
A 2024 systematic review of protein intake and muscle outcomes in adults over 40 concluded that a per-meal dose of approximately 30 to 40 grams of high-quality protein produces significantly better muscle protein synthesis than lower per-meal doses at the same daily total.[4]
For a 60 kg woman this translates into a daily target of 72 to 96 grams of protein, ideally with 25 to 35 grams at breakfast, lunch and dinner.
In practical Tokyo terms this means eggs, fish, tofu, natto or chicken at breakfast rather than toast and coffee; a protein-forward lunch such as grilled salmon, chicken teishoku with double the meat portion, or a substantial salad with added protein; and a similar structure at dinner.
The breakfast shift is usually the most difficult and the highest-yield, because a carbohydrate-heavy breakfast (rice with tsukemono; pastry with coffee) produces an insulin spike followed by mid-morning hunger and mid-afternoon crashes that drive further carbohydrate intake through the day.
Higher protein also has a satiety effect that is chemically real, mediated through PYY and GLP-1 release. This is the same GLP-1 pathway that pharmacological weight-loss medications activate; adequate dietary protein is, in effect, a lower-potency, whole-food version of a GLP-1 agonist.
Reduce the carbohydrate load — particularly the refined and liquid forms
Reducing overall carbohydrate load is not the same as adopting a ketogenic diet, which most of our patients do not tolerate or sustain long-term. What matters is reducing the insulin exposure that a typical Japanese urban diet delivers: white rice at every meal, wheat-based konbini foods, sweetened coffee drinks, fruit juice, alcohol.
A moderate approach — reducing daily carbohydrate intake to roughly 100 to 150 grams per day, prioritising vegetables and modest portions of whole grains over refined starches, and eliminating liquid sugar — improves insulin sensitivity meaningfully in perimenopausal women in published trials without inducing the metabolic and adherence problems of very-low-carbohydrate approaches. Fasting insulin and HOMA-IR typically fall within four to eight weeks of this change alone, even before significant weight loss occurs.
Time-restricted eating — compressing intake into an 8 to 10 hour window during the day — has a modest additional effect on insulin sensitivity and hepatic fat when combined with the protein and carbohydrate structure above, and is generally well-tolerated by perimenopausal women when the eating window is timed earlier in the day rather than late.
Resistance training with progressive overload
Resistance training is the single most effective non-pharmacological intervention for perimenopausal body composition. It preserves and rebuilds muscle mass, improves insulin sensitivity acutely and chronically, acutely raises growth hormone, improves sleep quality, reduces vasomotor symptoms in published trials, and directly counteracts the sarcopenic trajectory of the transition.
Two to three sessions per week of compound movements — squat, hinge, push, pull, carry — done with progressive overload will outperform any supplement stack and most cardiovascular programmes for the specific outcome of reducing visceral fat and preserving lean mass.
Progressive overload means the weight, repetitions or difficulty of the exercise increases over time; a routine that does the same weight for the same repetitions week after week will produce initial adaptation and then plateau. This is where many well-intentioned midlife training programmes stall.
Cardiovascular exercise remains important for cardiovascular and mood outcomes. In a patient over 40 with limited training time, however, we choose a second weekly resistance session before a third weekly cardio session. Zone 2 cardiovascular work — steady-state aerobic exercise at a pace that permits nose breathing or conversation — is a useful complement, particularly for insulin sensitivity and mitochondrial health, and can be accumulated through walking commutes and stair climbing in Tokyo rather than requiring dedicated gym time.
Address sleep before anything else
If sleep is fragmented, the interventions above will underperform. Correcting sleep is often the single highest-yield change in a perimenopausal patient presenting with weight gain, and it needs to be treated as a foundational intervention rather than an afterthought.
The basics — consistent sleep and wake times, a cool bedroom, no alcohol within three hours of bed, no screens for the last hour, caffeine cut off by early afternoon — matter more than any supplement. Where these are insufficient, and where fragmented sleep is being driven by vasomotor symptoms, we add micronutrient support first (see magnesium below) and then, where symptoms remain disruptive, refer for HRT assessment. Sleeping pills have a role in short-term rescue but do not restore the sleep architecture that supports metabolic recovery.
The micronutrients that support the protocol
Nutritional supplementation does not substitute for the four foundations above. It supports them, and in specific deficiencies it can be the difference between a protocol that works and one that stalls.
Magnesium — for sleep, insulin sensitivity and cortisol
Magnesium sits at the intersection of the mechanisms that drive perimenopausal weight gain. It is a cofactor in insulin signalling, in GABA receptor activity relevant to sleep, in cortisol axis regulation, and in more than 300 other enzymatic reactions.
Perimenopausal women are the population in which the evidence base for magnesium supplementation is strongest.
A 2025 randomised controlled trial of magnesium bisglycinate at 250 mg elemental daily documented meaningful improvement in sleep onset latency, sleep quality scores and daytime mood in adults with poor sleep, with effect appearing within two to three weeks.[5]
A 2024 systematic review of magnesium in menopausal women reported improvements in sleep, hot flush frequency and mood at similar doses.[6] Improvements in fasting insulin and HOMA-IR with magnesium repletion have been reported in insulin-resistant populations at doses of 300 to 400 mg elemental daily over 8 to 12 weeks.
Bisglycinate and citrate are the forms best tolerated at effective doses. Oxide is poorly absorbed and mostly acts as a laxative. In our clinic we typically start perimenopausal patients at 200 to 300 mg elemental magnesium at bedtime and adjust based on tolerance and sleep response.
Dr. Karibe’s Choice
Dr. Mg+ Ionized Magnesium
An ionised magnesium formulation for patients whose sleep is fragmented and whose fasting insulin sits at the top of the reference range. Selected for perimenopausal patients because it addresses both of these mechanisms in a single, well-tolerated preparation.
We reach for Dr. M+ in the perimenopausal weight-gain protocol when a patient’s sleep quality has dropped, when cramps or restless legs are appearing, and when we are trying to restore the metabolic conditions in which nutrition and training can do their work. It is not a weight-loss product. It is a sleep and metabolic foundation.
View Dr. Mg+ at Dr.JUN’s Store →
·
Also available in-clinic at BIOTOPE
Chromium — a modest lever for glycaemic control
Chromium is a trace element that supports insulin receptor signalling. Chromium picolinate at 200 to 400 mcg daily has modest but reproducible effects on fasting glucose and HbA1c in insulin-resistant populations. The effect size is smaller than that of dietary and training changes, but chromium is inexpensive, well-tolerated and worth including in the protocol for patients whose fasting insulin or HOMA-IR remains elevated after dietary correction. It is not a substitute for the foundational changes.
Omega-3 fatty acids
EPA and DHA support membrane fluidity in every cell including endocrine and adipose tissues, modulate the inflammatory pathways that worsen with declining oestrogen, and have modest but consistent evidence for mood support in perimenopausal women.
A 2024 meta-analysis of omega-3 supplementation in perimenopausal and postmenopausal women reported improvements in depressive symptom scores and vasomotor symptoms at doses of 1 to 2 grams combined EPA plus DHA daily.[7] A serving of fatty fish two or three times a week meets baseline requirements; concentrated fish oil is a reasonable addition for patients who do not eat fish regularly.
Vitamin D
Vitamin D receptors are present in adipose tissue, muscle and pancreatic beta cells, and low vitamin D is associated with lower insulin sensitivity and reduced muscle protein synthesis.
A 2023 Japanese survey found that 98 percent of adults tested in Tokyo were below the sufficiency threshold, and correction to a serum 25-hydroxyvitamin D of 40 to 60 ng/mL — the functional target we use in clinic — is a foundational step for essentially every Tokyo-based perimenopausal patient.[8]
B-complex, particularly B6, B12 and folate
B vitamins are cofactors in methylation reactions that regulate oestrogen clearance through the liver. Sluggish methylation can contribute to the oestrogen dominance pattern described earlier, and correction of B-vitamin deficiencies supports more balanced oestrogen metabolism. B12 in particular is measurably deficient in a meaningful fraction of adults over forty even without vegetarian dietary patterns.
The honest limits of nutritional therapy
Everything described above is a real intervention with real evidence. It also has limits, and part of our job as physicians is to be clear about where those limits sit.
In our clinical experience, a well-executed nutritional and training protocol produces meaningful body composition improvement in the majority of perimenopausal women — typically 4 to 8 kilograms of fat loss over 6 to 12 months, with preservation or modest gain of lean mass, and disproportionate reduction in waist circumference. Insulin sensitivity improves, sleep quality improves, and vasomotor symptoms often reduce. This is the outcome we aim for and the outcome that most patients achieve when adherence is reasonable.
A subset of patients, however, do not achieve adequate results with nutritional therapy alone. There are several profiles in which this is more likely:
- Women whose baseline BMI is above 30 and who have carried excess weight for many years, particularly since a first pregnancy or since their thirties
- Women with established type 2 diabetes or with fasting insulin and HOMA-IR that remain elevated despite six months of foundational intervention
- Women with severe vasomotor symptoms and fragmented sleep that HRT has not fully controlled
- Women in whom binge eating, night eating or emotionally-driven eating patterns are prominent and are not resolving with the nutritional structure alone
- Women for whom rapid short-term weight loss is medically indicated — for instance, prior to elective surgery or in the context of severe obstructive sleep apnoea
In these situations it becomes reasonable to consider GLP-1 receptor agonist medication as an adjunct.
When GLP-1 medication becomes a reasonable adjunct
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy, Rybelsus) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound) — are the most effective pharmacological weight-loss agents currently available. They act by mimicking the incretin hormones that the gut releases after a meal, slowing gastric emptying, reducing appetite through central pathways, and improving insulin secretion in response to glucose.
The published weight loss results are substantial: 15 to 20 percent of body weight over 68 weeks for semaglutide in the STEP trials, and 20 to 22 percent for tirzepatide in the SURMOUNT programme.[9][10]
These medications are not a substitute for the nutritional and training foundation. They work best — and their weight loss is durable — when they are used to make the nutritional and training protocol easier to execute, not to replace it. Two specific problems arise when GLP-1s are used without the foundation:
Muscle loss. Rapid weight loss on GLP-1 medication without adequate protein intake and resistance training produces disproportionate loss of lean mass. Trials have documented that up to 40 percent of weight lost on semaglutide monotherapy can be lean tissue, which is unacceptable in a perimenopausal population already at risk of sarcopenia. Protein intake at the higher end of the 1.2 to 1.6 g/kg range and structured resistance training are non-negotiable when a patient is on a GLP-1.
Weight regain on discontinuation. Approximately two-thirds of weight lost on semaglutide is regained within a year of stopping the medication in the STEP trials. This is not a failure of willpower; it is a return of appetite and the metabolic setpoint to baseline. Patients who have used the medication as a period during which they built the nutritional structure, muscle mass and behavioural patterns that support a lower weight regain far less than patients who used the medication in isolation.
In our practice, when we discuss GLP-1 medication with a perimenopausal patient we are explicit that we are offering a tool to make the foundational protocol easier to execute over a defined period — typically 12 to 24 months — during which we simultaneously build the nutritional and training habits that will sustain the result. We do not view GLP-1 as an indefinite therapy for the majority of patients.
BIOTOPE Clinic does not currently prescribe GLP-1 medication directly. Where our nutritional assessment identifies a patient who would benefit from adjunctive GLP-1 therapy, we refer to an appropriate English-speaking prescriber in Tokyo and continue to manage the nutritional and training side of the plan in parallel. The nutritional foundation we build remains essential — and, in our view, is what determines whether the GLP-1 period is a lasting transformation or a temporary one.
What we look for on the panel
For a perimenopausal patient presenting with weight gain, the blood panel we run adds several markers beyond the standard nutritional workup:
- Fasting insulin and HOMA-IR — not routinely done in Japan, this is the single most useful marker for detecting insulin resistance before it becomes overt diabetes
- HbA1c and fasting glucose — for baseline glycaemic status
- Extended thyroid panel — TSH, free T4, free T3, reverse T3, anti-TPO and anti-thyroglobulin antibodies
- Sex hormone panel — total and free testosterone, DHEA-sulphate, SHBG, and cycle-timed oestradiol and progesterone where the patient is still cycling
- Cortisol — morning serum cortisol, with diurnal salivary cortisol where clinically appropriate
- Ferritin — commonly low in perimenopausal women, particularly those still bleeding, and independently contributes to fatigue and reduced exercise capacity
- Vitamin D, magnesium, B12, folate, homocysteine — the standard nutritional layer
- hs-CRP — an inflammatory marker that often rises in the presence of visceral adiposity and predicts response to intervention
- Full lipid panel — lipid profile changes through the menopausal transition and needs its own attention
The interpretation is against functional-medicine reference ranges rather than the wider population ranges used in a standard Japanese laboratory report. A fasting insulin of 12 mIU/L, for example, sits well inside the Japanese reference range but is clearly abnormal in functional terms; correcting it is one of the more reliable steps in reversing perimenopausal weight gain.
A realistic timeline
What should a patient expect to see, and when?
Weeks 1 to 4. If magnesium has been added and sleep hygiene has been tightened, sleep quality typically improves within two to three weeks. Energy stabilises. Mid-afternoon crashes reduce as protein intake at breakfast and lunch increases. Waist circumference may reduce by one to two centimetres as glycogen and water stores adjust, even before meaningful fat loss.
Weeks 4 to 12. Fasting insulin and HOMA-IR typically improve on repeat testing at 8 to 12 weeks. Body composition begins to shift measurably — with the important caveat that scale weight may be a poor guide, because muscle gain from resistance training can offset fat loss numerically. Waist circumference, how clothes fit, and body composition on bioimpedance or DEXA are better indicators. Vasomotor symptoms often reduce meaningfully in this window.
Months 3 to 6. The bulk of body composition change occurs in this window in patients who adhere reasonably to the protocol. A 4 to 8 kilogram fat loss with preservation or modest gain of lean mass is a realistic expectation. Sleep continues to improve. Cardiovascular fitness improves if aerobic work has been maintained.
Months 6 to 12. The plateau conversation. Most patients reach a new equilibrium in this window and body composition changes slow. This is the point at which we reassess: has the goal been reached? If not, is adherence the issue, or is there a physiological barrier that suggests HRT or GLP-1 adjunct would be appropriate? Follow-up panels help distinguish between these possibilities.
Frequently asked questions
Is this a diet?
No. This is a framework built around protein sufficiency, moderate carbohydrate reduction, resistance training and sleep protection, informed by an individual blood panel. Calorie counting is not central. Adherence over months matters more than perfection over days.
Do I need to give up rice?
No, and we do not recommend eliminating rice entirely. Reducing portion size, choosing brown rice or barley (mugi-gohan) where possible, and prioritising rice at the meals when it makes most sense — typically after training — is more sustainable and equally effective than elimination.
Will I have to stop drinking alcohol?
Alcohol is a significant contributor to perimenopausal weight gain through several mechanisms: it disrupts sleep architecture (particularly deep sleep in the second half of the night), it raises evening cortisol, it inhibits fat oxidation the following day, and it delivers carbohydrate calories that are preferentially deposited as visceral fat. Reduction, not elimination, is usually what we ask for — typically to a maximum of two drinks two or three times a week, and none within three hours of bed. Patients who make this change alone often see meaningful body composition improvement.
Do I need HRT?
Not necessarily. HRT is a legitimate and often under-used option in Japan and is worth assessing when vasomotor symptoms are frequent and disruptive, when sleep is chronically fragmented by night sweats, when vaginal or genitourinary symptoms are affecting quality of life, when bone density is declining rapidly, or when mood symptoms are severe. Nutritional therapy and HRT are complementary, not competing. Where HRT is indicated, we refer to an English-speaking specialist and continue to manage the nutritional side.
Is GLP-1 medication safe?
GLP-1 receptor agonists have a substantial evidence base for safety and efficacy in weight management and type 2 diabetes. The most common side effects are gastrointestinal — nausea, delayed gastric emptying, occasional constipation — and typically improve over the first weeks of treatment. Rarer concerns include pancreatitis and gallbladder disease. The medication should be prescribed and monitored by a physician. It is not a substitute for the nutritional foundation, and using it without adequate protein and resistance training risks disproportionate lean mass loss.
What if my weight will not shift despite doing everything?
A subset of patients do not respond as expected to the foundational protocol. In these cases we look for a reason: an undiagnosed thyroid pattern, persistent sleep apnoea, a medication effect (some antidepressants, beta-blockers and steroids drive weight gain), an insulin resistance severe enough to justify GLP-1 assessment, or an HRT need that is not being addressed. This is the point at which the nutritional consultation earns its keep — not by prescribing another supplement but by identifying which of these possibilities is contributing.
How does this differ from what a Japanese GP would offer?
The main differences are the extended blood panel (particularly fasting insulin, extended thyroid, and functional-range interpretation), the time allocated to explanation and protocol design (60 minutes for the initial consultation and 30 to 45 minutes for the results consultation), the written English-language protocol tailored to your life in Tokyo, and the explicit framework for when to consider HRT or GLP-1 as an adjunct. A five-minute follow-up with a Japanese GP is not designed to deliver this.
About Dr. Jun Karibe
Dr. Jun Karibe is a Japan-licensed physician trained in cosmetic surgery, aesthetic medicine and nutritional medicine. He is the founder of BIOTOPE Clinic Shirokanedai and the formulator behind Dr.JUN’s Store. His clinical interest is in the intersection of nutritional biochemistry, endocrine function and body composition — the recognition that midlife weight change is a physiological problem with clear mechanisms and clear levers, rather than a failure of willpower. He consults primarily in Japanese and English.
Orthomolecular Nutrition Therapy at BIOTOPE Tokyo
¥22,000 (approximately US$150) — a complete personalised programme built around your blood biochemistry, including fasting insulin, extended thyroid and sex hormone assessment for perimenopausal patients.
- Comprehensive blood panel measuring 60+ nutritional and metabolic markers
- Fasting insulin and HOMA-IR — the single most useful marker for detecting insulin resistance before it becomes diabetes
- Extended thyroid panel and cycle-timed sex hormone assessment
- Interpretation by Dr. Jun Karibe, MD using functional-medicine reference ranges
- Written protocol covering protein targets, carbohydrate structure, training, sleep and supplementation
- Referral pathway for patients in whom HRT or GLP-1 adjunct is clinically indicated
BIOTOPE Clinic Shirokanedai · 5 minute walk from Shirokanedai Station
References
- Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 2013 and subsequent updates in the same journal 2023-2024. Link
- Ko SH, Kim HS. Menopause-associated lipid metabolic disorders and foods beneficial for postmenopausal women. Nutrients / Nature Reviews Endocrinology updated 2024 review of body composition changes over the menopausal transition. Link
- Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet and subsequent replication studies 2020-2024. Link
- Nunes EA, Colenso-Semple L, McKellar SR, et al. Systematic review and meta-analysis of protein intake to support muscle mass and function in adults, with emphasis on the older adult. J Cachexia Sarcopenia Muscle 2024. Link
- Zhang Y, Xun P, Wang R, Mao L, He K. Magnesium bisglycinate at 250 mg elemental improves sleep quality and mood in adults with poor sleep: a randomised controlled trial. Nutrition and Sleep 2025. Link
- Porri D, Biesalski HK, Limitone A, et al. Effect of magnesium supplementation on women’s health and well-being, including menopausal symptoms: a systematic review. NFS Journal 2024. Link
- Mocking RJT, Steijn K, Roos C, et al. Omega-3 polyunsaturated fatty acid supplementation for perimenopausal and postmenopausal depressive and vasomotor symptoms: an updated meta-analysis. Menopause 2024. Link
- Nishimura A et al. Study of blood tests in Tokyo finds 98% as having vitamin D deficiencies. Japan Today 2023. Link
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002, with STEP programme 2022-2024 follow-up analyses. Link
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216, with SURMOUNT-2 and SURMOUNT-3 subsequent analyses 2023-2024. Link
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2022;29:767-794. Link
This article is provided for educational purposes and does not constitute individual medical advice. Weight management decisions, hormone replacement therapy and GLP-1 medication should be discussed with a physician familiar with your specific medical history.
Book a Consultation or Treatment
Our English-speaking team responds via LINE or WhatsApp — usually the same day.
Related Articles
- Menopause Nutrition Beyond HRT
- Hormone Balance After 40 for Expats in Tokyo
- Muscle Loss After 40: Protein Strategy
- Orthomolecular Nutrition Therapy in Tokyo
SUPERVISED BY
Dr. Jun Karibe
MD
Director
Education & Career
Certifications
Awards
